XClose

UCL Queen Square Institute of Neurology

Home
Menu

UCL front runner in academic-industry partnerships

1 January 1970

Publication date: Nov 6, 2014 12:29:11 PM

A report in Nature Biotechnology shows UCL landing ahead of both Oxford and Cambridge in terms of industrial deals. In fact only Harvard University and the University of Texas system were more successful. The analysis of 387 public-private partnerships (including research institutes) shows cancer and infectious disease as major areas of interest, as well as diagnostics/pharmacogenetics and neurology.

University College London (6 deals, including):

  • Sarepta Therapeutics, Institute of Child Health,UCL Dubowitz Neuromuscular Centre (Duchenne Muscular Dystrophy): EU Health 2012 Innovation-1 research grant of undisclosed amount
  • Eli Lilly (Neurodegeneration) : Wellcome Trust Pathfinder Award of up to £100,000 for 18 months
  • Horizon Discovery (Huntington’s): Horizon granted exclusive rights to university-generated cell lines and option on new IP
  • Eisai (neurological diseases): Target discovery. University receives undisclosed milestones and royalties

Read More

Huggett, B. Academic-industry partnerships 2012. Nature Biotechnology, Volume:31, 383 (2013) doi:10.1038/nbt0513-383. Published online 08 May 2013